A combination of computation techniques have been used to determine the binding site and amino acid residues on IgE that are critical for binding to a therapeutic anti-IgE. Homology modeling was used to model parts of IgE and of an antibody that binds to IgE. Docking simulations using shape descriptions were then carried out using the models to determine which residues in the IgE are involved in the binding interaction. The anti-IgE has been determined to bind close to some of the residues that are believed to be in the Fc ε RI receptor site on IgE, therefore preventing IgE from binding to Fc ε RI on mast cells and basophils and causing the release of pharmacologic mediators from these cells. Experiments have been suggested to verify the binding site and the residues involved in binding to anti-IgE.
Introduction
Immunoglobulin E (IgE), one of the five classes of antibodies in the human immune system, which accounts for a minute proportion of immunoglobulin in the blood, is mainly responsible for immediate-type hypersensitivity reactions, causing common allergic diseases such as asthma and hay fever (Janeway and Travers, 1994) . The immune system was evolved to be highly redundant, having several mechanisms mediating overlapping immune defense functions. While IgE might have played a beneficial role in the immune defense in the evolution of the ancestor species of many animals, it seems to be dispensable for people living in most parts of the world. People with non-detectable or very low levels of IgE in blood live normal lives without impairment of immune defense (Levy and Chen, 1970) .
IgE exists in two forms, soluble secreted IgE (sIgE) and membrane-bound IgE (mIgE) on B cells, each consisting of two sets of two identical chains. The heavy chains (H chains) have one variable domain and four constant domains, and the light chains (L chains) one variable and one constant domain. The H chain of mIgE also has a membrane-anchoring peptide extending from its C-terminus. sIgE binds via its third constant heavy domain (CH3) to its high affinity receptor (Fc ε RI) on mast cells and basophils (Geha et al., 1985; Helm et al., 1989; Beavil et al., 1993) . Presta and co-workers (Presta et al., 1994) have determined the amino acid residues on IgE involved in binding to this receptor. The six residues which appear to be essential for binding to Fc ε RI are Arg408, Ser411, Lys415, Glu452, Arg465 and Met469 [Kabat numbering system for Ig's (Kabat et al., 1991) ]. In an allergic response, the multivalent antigen binds to IgE on mast cells and basophils, cross-linking IgE and thereby aggregating Fc ε RI, thus triggering the release of histamine and other pharmacologic mediators.
Recently an IgG1 protein has been developed that binds to IgE and is effective in eliminating allergy reactions (Chang et al., 1990; Davis et al., 1993) . It is believed that the antiIgE binds close to the Fc ε RI binding site on the IgE molecule and thus prevents sIgE from binding to its high affinity receptor on the basophils. This humanized IgG1 anti-IgE (Kolbinger et al., 1993) does not bind to the IgE from chimpanzees (Davis et al., 1993) which has two different residues (Gln424 instead of Glu and Val469 instead of Met) from the human version of this domain (Flanagan and Rabbitts, 1982; Kenten et al., 1982; Max et al., 1982; Sakoyama et al., 1987) . This implies that one of the two or both human unique residues are probably located in or very close to the binding site on IgE for the antiIgE antibody.
The objective of this work is to locate this binding site using a combination of computational tools. First, homology modeling was used to generate structures for IgE and the antiIgE since neither of the protein structures have been determined experimentally. Homology protein modeling has been objectively evaluated by comparing 'blind' predictions with experiments. In general, the assessment showed that a protein sequence with at least 40% identity to a known structure can be modeled with an accuracy approaching that of a lowresolution X-ray structure (Sali, 1995) . The sequence identity between anti-IgE and known X-ray structures is approximately 80% whereas the sequence identity between IgE and its template is lower (31%) but the corresponding sequence similarity where residues are taken to be of a similar type (aliphatic, non-polar, aromatic, polar, positively charged and negatively charged) is 48% (see Materials and Methods). Second, the resultant models of IgE and anti-IgE were evaluated using stereochemical tests and three-dimensional energy profiles to determine whether the structures produced were viable. Third, protein-docking algorithms were used to locate distinct potential anti-IgE binding sites on the IgE CH3 domain and to dock the Fv region of the anti-IgE into the sites on the IgE. Molecular docking programs have successfully predicted the correct overall mode of binding of a 165 amino acid inhibitor (β-lactamase inhibitory protein) to a 262 amino acid enzyme (TEM-1 β-lactamase) (Schoichet and Kuntz, 1996; Strynadka, 1996) , whose overall size is comparable to the present IgE/ anti-IgE complex (see Materials and methods). Fourth, the docked orientations were clustered and the distinct configurations were refined using Monte-Carlo minimization (Feng et al., 1996) to allow for conformational changes upon binding. Details of each of the above steps are presented in the next section.
Materials and methods

Homology modeling of IgE and anti-IgE
The majority of the CH2 domain (residues 315-359), the CH3 domain (residues 361-476) and the first 10 residues from the CH4 domain (residues 497-505) of IgE was modeled using the Modeller program (Sali and Blundell, 1993) . The fragment variable (Fv) region of the anti-IgE which contains the six hyper-variable loops that all antibodies involve in binding to an antigen (Clothia and Lesk, 1987; Chothia et al., 1989; Chothia, 1991) was modeled using the specialized antibody modeling program Xabgen (Mandal et al., 1996) . All template structures (Marquart et al., 1980; Deisenhofer et al., 1981; Padlan et al., 1989; Schiffer et al., 1989; Saul and Poljak, 1992; Edmundson et al., 1993) were taken from the Brookhaven Protein Database. The sequence alignments for anti-IgE and were taken from the Brookhaven Protein Database. The sequence alignments for anti-IgE and IgE are shown in Figures  1 to 3 . For IgE the CH2, CH3 and CH4 domains were aligned with the CL, CH2 and CH3 domains respectively from IgG. The resulting sequence identity was 31% but the sequence similarity where residues were taken to be of a similar type [aliphatic, non-polar, aromatic (excluding histidine), polar, positively charged (including histidine) and negatively charged] was 48%. In the case of the two Fab chains the sequence identity was approximately 80%. The resultant models were analyzed using the Procheck program (Laskowski et al., 1993; Laskowski et al., 1996) . Following the sequence alignment and the homology modeling the structures were energy minimized using the AMBER all-atom force field (Weiner et al., 1984 (Weiner et al., , 1986 ) for a few steps to remove any bad contacts. Subsequently, the energy profile and Z-score were computed for the IgE model using the ProsaII program (Sippl, 1993) as an addition test of the structure. All calculations were performed on either SGI R8000 Indigo 2 or SGI R5000 O 2 machines with a distancedependent dielectric constant and a long range non-bonded cutoff of 15 Å.
Rigid body docking of IgE and anti-IgE
Potential binding sites on the IgE were located by creating the molecular surface of the IgE protein, using Connelly's MS (Connolly, 1983a,b) program, and generating spheres to fill the cavities in this generated surface. The individual spheres were then clustered together so that overlapping spheres belong to the same cluster. A potential binding site was defined as a cluster containing at least 25 spheres. This process was carried out using the DOCK (Kuntz et al., 1982; Shoichet and Kuntz, 1991; Meng et al., 1992 Meng et al., , 1993 Shoichet et al., 1992) suite of 422 programs. Once the distinct potential anti-IgE binding sites on the IgE CH3 domain had been located the DOCK program was used to dock the Fv region of the anti-IgE into the sites on the IgE. Since the Fv region has in excess of 2000 atoms, spheres representing the molecular surface of the region constructed from the six hyper-variable loops, instead of atoms, were employed for the docking process. This reduced the number of elements from the Fv region to under 300 and greatly decreased the computational requirements of the calculations without reducing the accuracy. However this still required between 24 and 72 CPU hours using SGI R8000 Indigo 2 workstations. The AMBER force field was used to score the docked orientations and each orientation was minimized using a simplex minimizing routine built into the DOCK program. A grid-based method for the force field calculations was used [details can be found in (Meng et al., 1992) ] to further reduce the computation load. This method simplifies the calculation of the energy by only considering a box which contains the binding site. Instead of calculating the interactions on an atom by atom basis the box is divided up into a lattice (in our calculations each point was 0.55 Å apart) and a net potential is calculated for each grid point inside the box before any actual docking is performed. During the docking process all the force-field interactions are calculated using the predetermined lattice point potentials instead of the receptor atoms. Thus orientations were scored on force field binding energies which allowed the use of the minimizer to improve the docking. Only orientations that had a binding energy (∆E bind ) of less than Ϫ10 kcal/mol were accepted during the docking simulations. Each docked orientation was then subjected to quasi-Newton minimization using a continuum dielectric method instead of the grid-based method in the original docking calculations. This step eliminates any false low energy configurations that occur because of overlap of the molecules outside the box considered in the force field calculation. Clustering Since for some of the sites many similar docked orientations were produced the orientations were clustered as follows. For each site the orientation with the lowest ∆E bind was chosen as a reference to compute the heavy atom root mean square deviation (r.m.s.d.) for the rest of the orientations. The r.m.s.d. from the lowest energy orientation was plotted against ∆E bind (see Figure 4 ) and the orientations were grouped in clusters to reduce the number of configurations considered for the molecular dynamics stages. Each average structure from the clusters was then energy minimized using harmonic constraints on the backbone and side chain atoms to relieve close contacts in the protein without disrupting its overall conformation. This was performed using the AMBER4.1 (Pearlman et al., 1995) suite of programs. The resulting structure, consisting of 6649 atoms, was subjected to molecular dynamics using the AMBER program. The system was heated from 10 to 300 K over 3 ps, then 5 ps of equilibration followed by 20 ps of dynamics at 300 K using a 1 fs timestep and a distance-dependent dielectric constant with a nonbond cutoff of 15 Å. The coordinates from every 10 fs of the last 20 ps trajectory were averaged and the average structure was energy minimized for just enough steps to remove bad contacts.
Refinement
To allow for conformational changes upon binding the minimized averaged structure was subjected to cycles of Monte-Carlo minimization [details can be found in (Feng et al., 1996) ]. The initial structure was perturbed at 1000 K using molecular dynamics for 10 ps, followed by 10 steps of conjugate gradients energy minimization. If the energy of the new structure was lower than the previous one or if it passed a Metropolis type test then it was accepted and then perturbed for another 3 ps and minimized; if not it was rejected and the previous structure was again perturbed and minimized. This process was repeated 50 times. The lowest energy structure from this process was energy minimized for 500 steps and used as the initial structure for another cycle of Monte-Carlo minimization except that the temperature was lowered to 500 K. The lowest energy structure from the new cycle was tested to see if its energy was lower by more than 1 kcal/mol from the previous energy; if so this structure was taken as the initial structure for a new minimization cycle with the temperature reduced to 300 K. When the energy test of structures from two consecutive Monte-Carlo minimization cycles differed by less than 1 kcal/mol the process was halted and the final structures from the Monte-Carlo minimization were checked again using the Procheck program.
Analysis
The resultant IgE bound anti-IgE complexes were examined to see if the anti-IgE bound to the IgE fragment in a region close to the residues which differ between human and chimp IgE, since these residues are implicated to be in the binding site (see Introduction). Any orientation in which the human unique atoms were greater than 8 Å from any atom of the anti-IgE was discarded as being likely to be false. The remaining orientations were than analyzed to see which other residues from the IgE and anti-IgE were in close contact. The method of determining the close contacts was to calculate the solvent accessible surface area (SASA), using the Molmol (Koradi et al., 1996) program, of the IgE fragment with and without the presence of anti-IgE; any residue that had an altered SASA by greater than 1 Å 2 was used in the analysis. The analysis consisted of calculating the individual interaction energies between the IgE residues which had a different SASA and the anti-IgE molecule and determining whether there was a hydrogen bond (bond from hydrogen to an electronegative atom with distance ഛ2.4 Å and angle from linearity ഛ35°) from that residue to the anti-IgE.
Results
Validation of IgE and anti-IgE 3-dimensional structures
Using the alignments in Figures 1 and 2 , a model of the Fv region was generated by Xabgen. This model was energy minimized to give an energy of Ϫ2215 kcal/mol. An analysis of this structure using the Procheck program showed that 97% of the nonglycine and nonproline residues adopted either the most favorable or additional allowed regions on a Ramachandran plot. In other factors such as measurements of bad non-bonded interactions and peptide bond planarity the model met the requirements for a valid structure indicated by Procheck. An image of the molecular surface due to the hypervariable loops region composing of 290 spheres was created.
Twenty structures were generated for the IgE using the alignment in Figure 3 ; the model with the lowest objective function score was then energy minimized yielding an energy of Ϫ1827 kcal/mol. A Ramachandran plot generated by Procheck gave 95% of the nonglycine and nonproline residues in either the most favorable or additional allowed regions, five residues were in the disallowed regions but they are part of loop structures. Further tests by Procheck showed the model to comply to standards expected of a structure solved at 2.5 Å resolution. An energy profile test using the ProsaII program showed a few peaks in the profile in the CH3 domain. Further analysis showed that these peaks corresponded to residues in the loops connecting the well defined immunoglobulin β-strands. Energy profiles on the template structures also showed a similar presence of these isolated peaks. Z-scores of Ϫ6.8 for combined energies, Ϫ4.9 for pair energies and Ϫ5.0 for surface energies are within the limits for solved structures tested with ProsaII and the structure defeated all decoys in the ProsaII hide and seek test.
Binding sites
The initial search on the molecular surface of the IgE model gave four potential binding sites. The number of spheres in each site is listed in Table I . Each site was distinct from each other, comprising of more than 25 spheres. The results from the simulations docking the anti-IgE Fv region into each potential binding site on the IgE surface are also summarized in Table I . Each docked orientation was minimized further using a non-grid based method, and the lowest binding energies of each site are recorded in Table I . At this early stage it can be seen that site I does not seem to be involved in binding anti-IgE. Each of the other three sites are possible antiIgE binding sites with site III accommodating the most configurations and also producing the lowest interaction energy at Ϫ46 kcal/mol. Clustering of the docked orientations as described in the Materials and Methods was carried out. From the clustering, it was apparent that both orientations from site II were very similar while for site III there were three main clusters, the first (III-1) was composed of three orientations, the second (III-2) of seven and the third (III-3) of nine (see Figure 4 ). For site IV there were no other orientations close to the lowest energy orientation. The average structure for each cluster was generated and subjected to molecular dynamics simulation, followed by Monte-Carlo minimization; the final energies for each cluster and stage are listed in Table II . From the results in Table II it is apparent that the dynamics simulation and Monte-Carlo minimization protocols have successfully reduced the total energy for each IgE/anti-IgE complex. The total energy difference between the lowest energy orientation (III-2 at Ϫ6435 kcal/mol) and the highest (II-1 at Ϫ6335 kcal/ mol) is only 100 kcal/mol. Both of these structures were analyzed using Procheck to indicate the conformational changes after Monte-Carlo minimization. The integrity of the fold was retained but some relaxation of a few planar side-chain groups had occurred. Tests on the φ,ψ angle distributions, main chain bond lengths and angles as well as tests for bad non-bonded contact interactions indicated the model violations were comparable with the violations expected for a structure solved at 2.5 Å resolution. Following the docking, clustering and dynamics the distance between the human unique residues, Glu424 and Met469, and their closest contact on the anti-IgE was calculated. Since it is known that the anti-IgE binds to the human version of IgE and not the chimp version (Davis et al., 1993) then one or both of the human unique residues are likely to be located in the anti-IgE binding site. Table III shows the distance from the closest atom in the anti-IgE to the closest atom for each of the two human unique residues in the IgE CH3 domain. As can be seen from the table orientations III-1 and IV-1 are the only ones that dock close enough to the human unique residues to allow them to be involved in binding anti-IgE. In the case of the III-1 site both of the human unique residues are within the cutoff of 8 Å from the anti-IgE molecule while in the IV-1 molecule only Met469 is in close contact, whereas Glu424 is 17.8 Å from the closest atom in anti-IgE. SASA calculations were performed on IgE in the presence and absence of anti-IgE. The SASA differences are listed in Table  IV ; the individual binding energies of these residues to the anti-IgE are also listed, including the hydrogen bonds each residue has to anti-IgE. Figures 5 and 6 illustrate the binding of anti-IgE to the III-1 and IV-1 sites of IgE, respectively.
Discussion
From the three-dimensional structures of IgE and anti-IgE over 60 docked configurations were produced. Clustering 
-58.0 βG -9.5 Gly104 (-5.9) Ser476 -32.9 loop βG-CH4 -2.0 Gly497 -6.5 loop βG-CH4 -0.4 Pro498 -7.7 loop βG-CH4 -0.4 a The IgE CH3 domain consists of 7 β strands (denoted βA-βG) and 6 connecting loops (denoted loop AB-loop FG); loop βG-CH4 denotes the loops connecting βG to the CH4 domain. b Denotes residue hydrogen bonds to anti-IgE. c Denotes residue is believed to be involved in IgE-Fc ε RI binding. d Denotes human unique residue. Number inside brackets is the interaction energy between those two residues. narrowed this down to five different low energy configurations. By using a small but vital piece of knowledge from experimental results, the fact that the anti-IgE bound to human sIgE but not chimp sIgE, three of our docked configurations were deemed as false. Currently there are two possible binding sites on IgE for the anti-IgE molecule (Table IV , Figures 5 and 6 ). Each of these sites has one or more residues that Presta et al. (1994) indicated are involved in the binding of IgE to its Fc ε RI receptor. The SASA results for site III-1 shows that the majority of the binding occurs in two distinct areas of the CH3 domain, from residue 401 to 425, and from residue 457 to 466. A similar result is found for site IV-1 where the first contact area is from 367 to 369 and the second is from 463 to 476. This indicates that only certain loops from the six anti-IgE hyper-variable loops are involved in the binding; specifically for structure III-1 the anti-IgE binds using the L1, L3, H1, H2 and H3 hyper-variable loops, while the IV-1 complex binds using the L1, L3 and H3 hyper-variable loops on the anti-IgE. The binding energies in Table IV show that not all the residues in the binding site (of conformation III-1 or IV-1) 425 contribute equally to the binding of the anti-IgE molecule. In particular, the human-unique residue, Glu424 or Met469, does not appear to contribute to the net anti-IgE binding energy in either site III-1 or IV-1, respectively. The small SASA differences and negligible binding energy contributions from the human unique residues for each of the two sites considered imply that Glu424 or Met469 may play a structural role in stabilizing the active conformation for binding the anti-IgE molecule. In contrast, the positively charged IgE CH3 domain residues contribute over two-thirds of the binding energy in each site, indicating that electrostatic interactions mediate the binding between IgE and anti-IgE. Specifically, Lys415 and Arg457 in site III-1 and Arg465 and Arg470 in site IV-1 dominate the contributions to the anti-IgE binding energy. In each case, one of the positively charged residues, Lys415 in site III-1 and Arg465 in site IV-1, has been implicated in binding to the Fc ε RI receptor. This implies that binding of the anti-IgE to either site III-1 or IV-1 would inhibit binding of the Fc ε RI receptor since the binding site for anti-IgE appears to overlap with that for the Fc ε RI receptor. It also implies that the other positively charged residue, Arg457 in site III-1 or Table IV ) are white. Lys415, which is also implicated in IgE-Fc ε RI binding is highlighted in magenta, while Arg457 is in red. Table IV ) are white. Arg465, which is also implicated in IgE-Fc ε RI binding is highlighted in magenta, while Arg470 is in red.
Arg470 in site IV-1, may be responsible for the anti-IgE binding specificity.
Site-directed mutagenesis and nuclear magnetic resonance (NMR) experiments are suggested to distinguish between sites 426 III-1 and IV-1, and thus verify the predicted binding site. Since the key positively charged residues (Lys415 and Arg457 in site III-1 and Arg465 and Arg470 in site IV-1) bind to residues in the anti-IgE molecule via charge-charge and/or hydrogenbonding interactions, mutation of lysine or arginine to an aliphatic, neutral residue of similar size, like isoleucine or methionine, would abolish such interactions. Hence, if site III-1 was involved in binding anti-IgE, then mutating both Lys415 and Arg457 to isoleucine or methionine would diminish the binding affinity for anti-IgE (if there are no compensating interactions from nearby IgE residues), whereas changing both Arg465 and Arg470 to isoleucine or methionine would not significantly affect the binding affinity for anti-IgE (if the two arginine mutations do not cause a structural change in site III-1). Conversely, if site IV-1 was involved in binding antiIgE, then replacing both Arg465 and Arg470 with isoleucine or methionine would significantly reduce the binding affinity for anti-IgE (if there are no compensating interactions from nearby IgE residues), whereas substituting Lys415 and Arg457 with isoleucine or methionine would not significantly alter the binding affinity for anti-IgE (if the latter mutations do not alter the 'active' conformation of site IV-1). In addition to the double mutations, single substitutions of either Arg457 or Arg470 can be carried to test their role in conferring anti-IgE binding specificity by assessing the effect of the mutation on the binding affinity for the anti-IgE compared with the Fc ε RI receptor.
Since the results of site-directed mutagenesis experiments are not unambiguous; e.g., reduced binding affinity of the mutant IgE could also result from a conformational change of the molecule, the IgE binding site for the anti-IgE can be verified by selectively labeling the CH3 domain of IgE with 2 H, 13 C or 15 N and observing the chemical shift perturbation induced by the interaction with the anti-IgE molecule. Such NMR experiments have recently been employed to identify the protein L-binding site of an immunoglobulin light chain, using selectively 13 C-labeled amino acid residues, and measuring the carbonyl 13 C chemical shift perturbations induced upon formation of the Fab-protein L B1 domain complex (Enokizono et al., 1997) .
The results also contain information useful for designing antibodies for sIgE. We can tell which of the residues on the IgE are already strongly bound to the antibody and which are not. By mutating some of the residues on the anti-IgE antibody it would be possible to target some of the currently weakly binding residues to the IgE to improve the binding. For instance in site III-1 Lys415 and Arg457 contribute significantly to the binding energy but the other two positively charged residues (His419 and Lys423) are less involved in binding anti-IgE. Modifying the Lys423 closest residues in the anti-IgE from the current Phe to either Glu or Asp could increase the ∆E bind of this residue. Further, our results also suggest peptidyl candidates that may inhibit the binding of IgE to Fc ε RI.
In summary using the computational techniques outlined here with the knowledge obtained by experimental work we have determined two possible receptor sites that the derived anti-IgE could bind to IgE. With suggested experiments the actual binding site and recognition residues could be verified. Further analysis of our models can provide information that may aid in the design of improved agents for binding IgE, thus being more effective at preventing ailments caused by this protein.
